Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2024-04-16 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于使用部分闲置募集资金委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. regarding the use of part of idle raised funds for entrusted financial management. It details the amount of funds raised through convertible bonds, the intended investment projects, the decision-making process by the board, risk analysis, and opinions from the supervisory board and sponsor. The document is a formal disclosure about the company's capital management activities, specifically the use of idle raised funds for short-term financial products. It does not contain financial statements, audit results, or detailed financial performance data. It is not a full annual or interim report, nor is it a call transcript or management report. It is an update on financing activities related to the use of raised capital. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3646 characters, which is consistent with an announcement rather than a full report.
2024-04-16 Chinese
益丰药房第四届监事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 31st meeting of the 4th Supervisory Board of Yifeng Pharmacy Chain Co., Ltd. It details the meeting attendance, voting results, and specific proposals regarding the use of idle raised funds for temporary liquidity and entrusted financial management. The document is an official disclosure of board-level decisions rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis but focuses on governance and supervisory board decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2024-04-16 Chinese
中信证券股份有限公司关于益丰大药房连锁股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion issued by CITIC Securities regarding the use of idle raised funds by Yifeng Pharmacy Chain Co., Ltd. It discusses the temporary use of idle convertible bond funds to supplement working capital, including details about the raised funds, investment projects, board and supervisory opinions, and the sponsor's verification. The document is regulatory in nature, focusing on compliance with securities regulations and fund usage rules, without containing financial statements or comprehensive financial performance data. It is not an annual report, interim report, earnings release, or any other financial report type. It is also not a simple announcement but a formal verification opinion related to fundraising and fund usage. Therefore, it fits best under Regulatory Filings (RNS), which covers compliance documents and miscellaneous filings that do not fit other categories.
2024-04-16 Chinese
益丰药房关于开立募集资金专户并签署募集资金专户存储四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. regarding the opening of a special account for raised funds and the signing of a four-party supervision agreement related to the raised funds from a convertible bond issuance. It details the approval from the China Securities Regulatory Commission, the amount raised, the use of funds, the signing of agreements with banks and the sponsor (CITIC Securities), and the regulatory compliance and supervision mechanisms. The document does not contain financial statements or detailed financial performance data but is focused on the capital raising process and fund management. The length is 4025 characters, which is relatively short and the content is an announcement about fundraising and fund management rather than a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP).
2024-04-15 Chinese
益丰药房关于公司监事可转债短线交易情况说明的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a short-swing trading violation by a company supervisor involving convertible bonds. It details the transaction dates, amounts, legal references, and the company's response including the recovery of profits and an apology. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement about insider trading compliance and corrective actions, not a financial report or meeting material. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and focused on compliance disclosure, consistent with RNS filings.
2024-04-15 Chinese
益丰药房关于归还暂时用于补充流动资金的可转换公司债券募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the repayment of temporarily used convertible bond funds that were used to supplement working capital. It details the amount used and repaid, references previous announcements, and provides no financial statements or detailed financial analysis. The document is short (744 characters) and serves as an update on financing activities related to convertible bonds. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2024-04-08 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.